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There is little evidence on which to judge the optimal treatment for convulsive status epilepticus (CSE) in children. This study
compares the effect of intravenous (iv) lorazepam with iv diazepam as the firs line of treatment of CSE.
We studied all children with prolonged seizures arriving in the Accident and Emergency (A&E) Department in two separate
periods. In the firs 6-month period iv diazepam was used as standard treatment, in the second 1-year period iv lorazepam was
used. We measured latency to stopping of seizure and any adverse events. A successful treatment was define as one in which
the seizure clinically ceased within 15 minutes after siting the iv cannula, requiring no further treatment.
Intravenous diazepam (0.32 mg kg−1) was used in 17 of 26 patients, whilst iv lorazepam (0.13 mg kg−1) was used in 31 of 59.
There were no differences between the two groups regarding age, sex and seizure type.
The seizure was successfully controlled 15 minutes after siting the iv cannula in 11 (65%) patients treated with diazepam
(median time of 3 minutes) and in 20 (65%) patients treated with lorazepam (median time of 5 minutes).
These preliminary results suggest that iv lorazepam may be as effective as iv diazepam.
c© 2002 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
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INTRODUCTION
For many years diazepam has been used as the
firs line treatment for convulsive status epilepti-
cus (CSE). However recently many Accident &
Emergency (A&E) Departments have started using
lorazepam for children as the firs treatment, in
accordance with the current Advanced Paediatric Life
Support protocol1, and the recent evidence-based
guidelines from the British Paediatric Neurology
Association2.
Early and effective treatment is essential to prevent
the morbidity and mortality associated with prolonged
CSE. There is evidence that the longer the convulsion
the more difficul it may be to treat3 and there is also
a greater risk of long-term neurological sequelae4.
Lorazepam is preferred as it has a longer half-life,
possibly less respiratory depression5–7, and repeated
doses are less often required than with diazepam8.
AIMS
In view of these considerations the CSE protocol at the
Birmingham Children’s Hospital A&E Department
was changed to include intravenous (iv) lorazepam
as the firs line treatment. An audit of this protocol
change was then undertaken to compare the effica y
and safety of iv diazepam with iv lorazepam.
MATERIALS AND METHODS
Data was collected over two separate periods. The firs
6-month period was from September 1997 to March
1998. The second 1-year period was from March 1999
to March 2000. The study took place in the A&E
Department at Birmingham Children’s Hospital. Data
collection sheets were devised and nursing staff and
doctors were informed of the ongoing audit. Each
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time a patient came in to the department still in CSE,
requiring emergency treatment, the data sheet was
completed.
During the firs time period the protocol fir t line
treatment was iv diazepam 0.3 mg kg−1 and in the
second period the protocol firs line treatment was iv
lorazepam 0.1 mg kg−1. A repeat dose of the same
amount was to be given after 10 minutes if there had
been no response (see Figs 1 and 2).
ABC 
** Check BM ** 
Immediate IV access    No IV access 
Diazepam 0.3mg/kg iv  Diazepam rectal 0.5mg/kg  
      10 min                  10 min      10 min 
       
Diazepam 0.3 mg/kg IV Paraldehyde 0.4ml/kg PR  
10 min 
10 min 
      Iv or intra osseous 
Phenytoin iv or Phenobarbitone iv 
 20 mg/kg over 20 min   20 mg/kg over 10 min 
20 min 
Rapid sequence induction with thiopentone 4 mg/kg IV 
Fig. 1: Protocol for treating CSE in A&E in 1997/1998.
A successful treatment was define as one in which
the seizure clinically ceased within 15 minutes after
siting the iv cannula, requiring no further treatment.
Each patient’s vital signs were monitored, particularly
signs of respiratory depression. The patient’s age
and sex, length of seizure prior to admission, time
of admission to A&E, times of administration of
drugs, latency to clinically evident seizure control,
any recurrence of seizure or need for admission
to paediatric intensive care (PICU) were noted
prospectively on a data sheet. If initial treatment
was unsuccessful the next steps in the protocol were
followed which were iv phenytoin at 18 mg kg−1 as an
infusion over 20 minutes or, for children under 5 years
of age, phenobarbitone at 20 mg kg−1 over 10 minutes.
If iv access was initially not readily available rectal
diazepam and/or rectal paraldehyde was used. If all
the above interventions did not control the seizure
the treatment was taken over by PICU staff and
included rapid sequence induction with thiopentone
and ventilation with transfer to PICU 35–45 minutes
after arrival in A&E.
ABC 
** Check BM ** 
Immediate IV access  No IV access 
Lorazepam 0.1mg/kg iv  Diazepam rectal 0.5mg/kg  
      10 min                  10 min      10 min 
       
Lorazepam 0.1mg/kg IV Paraldehyde 0.4ml/kg PR 
10 min 
10 min 
       Iv or intra osseous 
Phenytoin iv or Phenobarbitone iv 
18 mg/kg over 20 min   20 mg/kg over 10 min 
20 min 
Rapid sequence induction with thiopentone 4 mg/kg IV 
(& If not received already, Paraldehyde 0.4ml/kg PR
 in equal volume olive oil) 
Fig. 2: Protocol for treating CSE in A&E in 1999/2000.
Table 1: Characteristics of the patients in the two treatment
groups.
Diazepam Lorazepam
Total no. patients 17 31
Mean age (range) yr 3.5 (0.5–8.0) 4.2 (1.0–11.0)
Mean weight (range) kg 14 (4.0–22.0) 18.2 (10.0–70.0)
No. male 6 (35%) 14 (45%)
Mean dose (range) mg kg−1 0.32 (0.15–0.5) 0.13 (0.05–0.2)
Statistical analysis, comparing the latency times to
control seizure, in the two groups was undertaken
using the Mann–Whitney test as the times had skewed
distributions. Medians and ranges are presented as
summary statistics.
RESULTS
The ages of the children in the two groups were
similar: the mean age of children given diazepam
(group 1) was 3.5 years and for the lorazepam
(group 2) was 4.2 years (Table 1). The protocol change
and the longer time period meant that there were more
children in group 2, 31 compared with 17 in group 1.
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Table 2: Comparison of treatment outcomes between the two treatment groups.
Diazepam Lorazepam
Median (range) seizure duration before
treatment (min)
45 (10–240) 35 (1–160) NS
Median (range) total seizure duration (min) 80 (17–250) 62 (15–206) NS
Number (%; 95%CI) who successfully*
stopped seizing after iv dose
11 (65%; 38–86%) 20 (65%; 45– 81%) NS
Median (range) time seizure stopped after
siting iv cannula (min) in all patients
5 (0.2–80) 11 (0.2–120) NS
Number requiring 2nd dose 1 4 NS
Median (range) latency to stopping of
seizure after a single iv dose only (min)
3 (0.2–15.0) 5 (0.2–15.0) NS
Number (%) requiring PICU 2 (12%) 6 (19%) NS
∗ A successful treatment was define as one in which the seizure clinically ceased within 15 minutes after siting the iv cannula, requiring no
further treatment.
NS: not statistically significant P > 0.05.
Fifty-six% of the diazepam group and 59% of the
lorazepam group received rectal diazepam en route to
the hospital by the paramedic crew.
The mean iv doses were: 0.32 mg kg−1 of diazepam
and 0.13 mg kg−1 of lorazepam. The seizure was
successfully controlled in 65% of patients treated
with diazepam and in 65% treated with lorazepam
(i.e. the seizure ceased within 15 minutes after siting
the iv cannula and required no further treatment
(see Table 2)). A greater proportion (53%) of the
convulsions stopped in the firs 5 minutes with
diazepam compared with lorazepam (42%) (Table 3).
This difference is not signifi ant.
In those patients who required only a single dose
of iv treatment to control their seizure, the median
latency for diazepam (n= 11) was 3 minutes and that
of lorazepam (n= 16) was 5 minutes in this study.
There were no statistically significan differences
between groups in respect of any the above times.
There were two patients admitted to PICU following
diazepam (12%) and six following lorazepam (19%).
Admission to PICU was either because the seizure re-
quired thiopentone induction (one child in each group)
or for observation after the prolonged convulsion with
concern about respiratory depression (three children
in the lorazepam group), or because the patient
was intubated and ventilated, or for management of
concomitant circulatory or respiratory failure (one
child in both groups had meningitis requiring PICU
care).
There were no other associated adverse events.
Seizures recurred in one of 12 (8%) patients
successfully treated with diazepam and in four of
20 (20%) patients treated with lorazepam. These are
not statistically significantl different. There were no
deaths in the study population.
Table 3: Duration of seizure in each treatment group.
Duration of seizure Diazepam Lorazepam
after iv cannula sited No. of PTS (%) No. of PTS (%)
<5 min 9 (53) 13 (42)
5–15 min 2 (12) 7 (23)
>15 min 6 (35) 11 (35)
The presumed aetiology of the convulsions was
similar in both groups (Table 4).
Table 4: Underlying diagnosis causing convulsion in patients
in the two groups.
Underlying diagnosis Diazepam group (%) Lorazepam group (%)
Febrile convulsion 4 (24) 11 (35)
Meningitis 2 (12) 2 (6)
Head injury 1 (6 ) 0 (0)
Epilepsy 10 (59) 19 (61)
DISCUSSION
There are difficultie in the methodology of such a
comparative audit. We compared data collected in two
different time periods with different observers and
different numbers of patients. Looking at the figure
it seems that lorazepam may have been as effective
as diazepam, although it may not be as rapid as
diazepam. The data was analysed statistically using
non-parametric tests. It was found that there was no
statistically significan difference between the two
groups for effica y or safety. Interestingly different
studies have found a range of latency of action for lo-
razepam. Table 5 shows the studies involving children.
An adult study (Homan et al.10) found diazepam to
have a median latency of 2 minutes and lorazepam
of 3 minutes. They found in their literature review
that most authors had quoted a latency of less than
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Table 5: Data from other studies quoting latency times for intravenous lorazepam (LOR) and diazepam (DIA).
Study No. Children Success rate Latency
Appleton et al. (1995) 6 86 evaluated 76% iv LOR 0.3–1 min LOR
51% iv DIA 0.3–1 min DIA
Crawford et al. (1987) 11 77 patients 79% iv LOR
Lacey et al. (1985) 9 31 patients 85% iv LOR Median 10 min
3 minutes for lorazepam; the longest latency they
found was 15 minutes.
In most studies both drugs were given as a single
iv injection over a period of 0.2–2 minutes, as in our
audit.
As far as overall success rate is concerned our figur
of 65% is less than in the quoted studies. There were
no unexpected adverse effects noted in either group,
however in both groups children were admitted to
PICU.
In view of the relatively low power of the study
it was not possible to detect small differences in the
effica y of the treatments being compared. In order to
detect a difference of 15 minutes in the mean stopping
time with a power of 80% and a significanc of 0.05,
a sample size of 56 patients for each group would be
required even with unskewed normal data. With our
sample size it would only be possible to demonstrate
a statistically significan difference in mean stopping
time of 25 minutes or more (80% power, P = 0.05).
With the large variability in the stopping times the
distribution is skewed to the right, necessitating even
larger sample sizes to detect moderate differences.
However the other outcomes suggest that there is
not a clinically significan difference in effica y, e.g.
in terms of relapse rate or admission to PICU.
From this audit we can conclude that lorazepam
seems at least as safe and effective as diazepam in
the treatment of convulsive status epilepticus. An
important point to emerge from this comparative audit
is that there were no adverse events associated with the
new protocol. This has allowed us to continue to use
iv lorazepam in the A&E Department with continuing
audit of outcome.
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